News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Eli Lilly and Company (LLY) Announces Discontinuation of Humatin (Paromomycin Sulfate Capsules, USP)


2/8/2008 7:39:08 AM

San Francisco, Calif. – Eli Lilly and Company has decided to stop producing Humulin U and Humulin L Insulins. According to a letter to health care providers, use of these longer-acting insulins has declined by more than 70% over the past five years due to newer insulin therapies. The company estimates less than 2% of diabetes patients in the U.S. will be affected by this discontinuation.

To view the letter to health care professionals, please visit: http://www.fda.gov/cder/drug/shortages/HumulinDr.pdf

Contact Suvarna Bhatt at sbhatt@biospace.com.


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES